Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial
Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial
复制标题
DOI：
10.1161/circulationaha.107.763912
复制
发表时间：
2009-04-21
期刊：
影响因子：
37.8
通讯作者：
Braunwald, Eugene
中科院分区：
文献类型：
--
作者：
Morrow, David A.;Scirica, Benjamin M.;Braunwald, Eugene
雷诺嗪是一种新型抗心绞痛药物，在糖尿病和慢性心绞痛患者中进行的探索性分析显示，雷诺嗪与血红蛋白A（1c）（HbA（1c））下降相关。我们设计了一个前瞻性评价雷诺嗪对高血糖症的影响作为一个随机，双盲，安慰剂对照outcomes trial.Methods和结果的一部分，我们比较了HbA（1c）（百分比）和发病的时间>= 1%的HbA（1c）增加之间的4918例急性冠脉综合征患者随机雷诺嗪或安慰剂在MERLIN-TIMI 36试验。与安慰剂相比，雷诺嗪在4个月时显著降低了HbA（1c）（5.9% vs 6.2%;较基线的变化，-0.30 vs-0.04; P
Background-Ranolazine is a novel antianginal shown in an exploratory analysis in patients with diabetes mellitus and chronic angina to be associated with a decline in hemoglobin A(1c) (HbA(1c)). We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial.Methods and Results-We compared HbA(1c) (percentage) and the time to onset of a >= 1% increase in HbA(1c) among 4918 patients with acute coronary syndrome randomized to ranolazine or placebo in the MERLIN-TIMI 36 trial. Ranolazine significantly reduced HbA(1c) at 4 months compared with placebo (5.9% versus 6.2%; change from baseline, -0.30 versus -0.04; P